作者:Mark J. Robertson、André Horatscheck、Samantha Sauer、Lisa von Kleist、Jennifer R. Baker、Wiebke Stahlschmidt、Marc Nazaré、Ainslie Whiting、Ngoc Chau、Phillip J. Robinson、Volker Haucke、Adam McCluskey
DOI:10.1039/c6ob02308h
日期:——
rhodanine-based lead that led to the Pitstop® 2 family of clathrin inhibitors is described herein. Head group substitution and bioisosteric replacement of the rhodanine core with a 2-aminothiazol-4(5H)-one scaffold eliminated off target dynamin activity. A series of N-substituents gave first phenylglycine (20, IC50 ∼ 20 μM) then phenyl (25, IC50 ∼ 7.1 μM) and 1-napthyl sulfonamide (26, Pitstop® 2 compound
(Z)-5-((6,8-dichloro-4-oxo-4 H -chromen-3-yl)亚甲基)-2-thioxothiazolidlid-4--4-one(2),基于罗丹宁的铅的开发本文描述了导致网格蛋白抑制剂Pitstop?2家族的产品。用2-氨基噻唑-4(5 H)-一个支架取代若丹宁核心的头基取代和生物等位取代可消除目标动力蛋白的活性。一系列ñ -取代基,得到第一苯基甘氨酸(20,IC 50〜20μM)然后苯基(25,IC 50〜7.1μM)和1-萘基磺酰胺(26,Pitstop®2化合物,IC 50〜1.9μM)具有良好活性的类似物,验证了这种方法。最后库探索头组促使三个类似物显示(无论是轻微的改进或相当的活性33,38,和29与IC 50分别〜1.4,1.6和1.8μM)和九人用IC 50 <10微米。使用计算机对接研究对这些结果进行了合理化。对接研究预测,在报道的网格蛋白突变